This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Hologic Teams Up With the CDC to Combat H5N1 Bird Flu: Stock to Gain?
by Zacks Equity Research
Via an agreement with the CDC, Hologic is set to develop ASRs for launching the H5N1 bird flu test.
Here's Why Hologic (HOLX) Fell More Than Broader Market
by Zacks Equity Research
Hologic (HOLX) closed the most recent trading day at $70.76, moving -0.99% from the previous trading session.
Hologic (HOLX) Stock Moves -1.93%: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Hologic (HOLX) stood at $73.64, denoting a -1.93% change from the preceding trading day.
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
TMO Institutional & Insider Stock Sell-Offs Upset Market: How to Play
by Urmimala Biswas
Investors are also concerned about Thermo Fisher's continuous decline in testing revenues due to the decline in COVID testing-related demand.
Hologic Trades at 17.62X P/E: Should You Buy, Sell or Hold the Stock?
by Moumi Mondal
Despite the current challenges, HOLX's portfolio strength and international growth prospects make it worth holding on to.
Hologic (HOLX) Down 1.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
HOLX Stock Set to Gain From New Study Data on Genius AI Detection 2.0
by Zacks Equity Research
Hologic upholds its focus on equity with new research findings on its Breast Imaging AI solution.
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know
by Zacks Equity Research
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hologic to Debut AI-Powered Innovations at RSNA 2024: Stock to Gain?
by Zacks Equity Research
HOLX will unveil breakthrough innovations at this year's RSNA, focusing on imaging solutions and AI.
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Should You Retain Hologic Stock in Your Portfolio Now?
by Zacks Equity Research
HOLX's strength in the Molecular Diagnostics wing instills optimism among investors. Yet, macro woes and currency impacts raise concerns.
Implied Volatility Surging for Hologic (HOLX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Hologic (HOLX) stock based on the movements in the options market lately.
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hologic Post Q4 Earnings Miss: Time to Buy, Hold or Sell the Stock?
by Moumi Mondal
Despite the recent earnings miss, Hologic's portfolio strength and capital allocation strategy can be appealing to investors.
Hologic Q4 Earnings Lag, Revenues Top, Stock Down in Aftermarket
by Zacks Equity Research
HOLX's fiscal 2024 fourth-quarter results underscore the durable growth of its businesses.
Hologic (HOLX) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Hologic (HOLX) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Hologic (HOLX) Q4 Earnings Miss Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of -0.98% and 0.88%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Steris (STE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Unlocking Q4 Potential of Hologic (HOLX): Exploring Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Hologic (HOLX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Hologic (HOLX) Stock Falls Amid Market Uptick: What Investors Need to Know
by Zacks Equity Research
In the latest trading session, Hologic (HOLX) closed at $80.46, marking a -0.46% move from the previous day.
Hologic (HOLX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Non-COVID-19 Diagnostics Sales Drive Hologic's Q4 Earnings?
by Zacks Equity Research
HOLX's fiscal 2024 fourth-quarter results are expected to reflect a solid performance of the Diagnostics business, led by the base Molecular franchise.
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.